TY - JOUR
T1 - Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2
T2 - A multi-center case-only analysis
AU - Moorman, Patricia G.
AU - Iversen, Edwin S.
AU - Marcom, P. Kelly
AU - Marks, Jeffrey R.
AU - Wang, Frances
AU - Lee, Eunjung
AU - Ursin, Giske
AU - Rebbeck, Timothy R.
AU - Domchek, Susan M.
AU - Arun, Banu
AU - Susswein, Lisa
AU - Isaacs, Claudine
AU - Garber, Judy E.
AU - Visvanathan, Kala
AU - Griffin, Constance A.
AU - Sutphen, Rebecca
AU - Brzosowicz, Jennifer
AU - Gruber, Stephen
AU - Finkelstein, Dianne M.
AU - Schildkraut, Joellen M.
N1 - Funding Information:
Acknowledgments This study was funded by the following grants and contracts from the National Cancer Institute, National Institutes of Health: P50-CA068438 Specialized Program of Research Excellence (SPORE) in breast cancer, Duke University Medical Center; Cancer Genetics Network (U01 CA78284 and HHSN 261200744000C), Massachusetts General Hospital.
PY - 2010/11
Y1 - 2010/11
N2 - The incomplete penetrance of mutations in BRCA1 and BRCA2 suggests that some combination of environmental and genetic factors modifies the risk of breast cancer in mutation carriers. This study sought to identify possible interactions between established breast cancer risk factors and BRCA1 or BRCA2 mutations using a case-only study design. Breast cancer cases that had been tested for BRCA1 and BRCA2 mutations were identified from 11 collaborating centers. Comparisons of reproductive and lifestyle risk factors were made between women with breast cancer who were positive for BRCA1 mutations (n = 283), BRCA2 mutations (n = 204), or negative for both BRCA1 and BRCA2 mutations (n = 894). Interaction risk ratios (IRRs) were calculated using multinominal logistic regression models. Compared with non-carriers, statistically significant IRRs were observed for later age at menarche among BRCA2 mutation carriers, for a greater number of pregnancies among both BRCA1 and BRCA2 mutation carriers, and for alcohol use among BRCA1 mutation carriers. Our data suggest that the risk for breast cancer among BRCA1 or BRCA2 carriers may be modified by reproductive characteristics and alcohol use. However, our results should be interpreted cautiously given the overall inconsistency in the epidemiologic literature on modifiers of BRCA1 and BRCA2.
AB - The incomplete penetrance of mutations in BRCA1 and BRCA2 suggests that some combination of environmental and genetic factors modifies the risk of breast cancer in mutation carriers. This study sought to identify possible interactions between established breast cancer risk factors and BRCA1 or BRCA2 mutations using a case-only study design. Breast cancer cases that had been tested for BRCA1 and BRCA2 mutations were identified from 11 collaborating centers. Comparisons of reproductive and lifestyle risk factors were made between women with breast cancer who were positive for BRCA1 mutations (n = 283), BRCA2 mutations (n = 204), or negative for both BRCA1 and BRCA2 mutations (n = 894). Interaction risk ratios (IRRs) were calculated using multinominal logistic regression models. Compared with non-carriers, statistically significant IRRs were observed for later age at menarche among BRCA2 mutation carriers, for a greater number of pregnancies among both BRCA1 and BRCA2 mutation carriers, and for alcohol use among BRCA1 mutation carriers. Our data suggest that the risk for breast cancer among BRCA1 or BRCA2 carriers may be modified by reproductive characteristics and alcohol use. However, our results should be interpreted cautiously given the overall inconsistency in the epidemiologic literature on modifiers of BRCA1 and BRCA2.
KW - BRCA1
KW - BRCA2
KW - Breast cancer
KW - Modifiers
KW - Mutations
UR - http://www.scopus.com/inward/record.url?scp=78649332243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649332243&partnerID=8YFLogxK
U2 - 10.1007/s10549-010-0842-y
DO - 10.1007/s10549-010-0842-y
M3 - Article
C2 - 20309627
AN - SCOPUS:78649332243
SN - 0167-6806
VL - 124
SP - 441
EP - 451
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -